Nalaganje...
Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)
BACKGROUND. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ∼4 mont...
Shranjeno v:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AlphaMed Press
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3286175/ https://ncbi.nlm.nih.gov/pubmed/22285963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0237 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|